AstraZeneca Plc’s AZN COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now, European Medical Agency (EMA) is investigating potential clotting risks from Johnson & Johnson’s JNJ one-shot COVID-19 vaccine.
What Happened: While AstraZeneca has been caught in a frenzy over possible links to rare blood clots and subsequent restriction on the usage of its vaccine, this is a formal disclosure of the J&J probe.
So far, four severe cases of rare blood clots with low platelets have been reported after inoculation with J&J’s vaccine.
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) said three cases of unusual blood clots with low blood platelets followed the vaccination. Another issue came in a clinical trial.
Why It Matters: All four were “serious cases,” the committee says. The reports “point to a ‘safety signal,’ but it is currently not clear whether there is a causal association,” PRAC says.
So far, the JNJ vaccine is only available in the U.S., but European officials recently authorized the jab, and the rollout is expected to start soon.
Meanwhile, the U.S. rollout of the JNJ vaccine has run into some problems. Just 785,000 doses are set to ship out to states next week, down from 4.9 million this week.
In Colorado and North Carolina, two vaccination sites temporarily closed this week after adverse reactions in a limited number of recipients, CBS News reports.
J&J’s vaccine has also been in the news lately due to manufacturing missteps at its partner Emergent BioSolutions when workers at an Emergent plant in Baltimore ruined 15 million doses of vaccines. In response, the Biden administration put J&J in charge at the plant.
That forced AstraZeneca, which had also partnered with Emergent, to look for a new manufacturing partner.
The European agency also said five cases of capillary leak syndrome linked to AstraZeneca’s vaccine were reported. The condition in which blood leaks from the smallest of vessels into muscles and body cavities is characterized by swelling and a drop in blood pressure.
However, the EMA has said that “at this stage, it is not yet clear whether there is a causal association” between the vaccines and the reported conditions, Reuters reported.
Additionally, an Indian government panel of experts is investigating for any domestic cases of blood clotting, even mild ones, as a side effect of the two COVID-19 vaccines being administered in India, financial daily Mint reported.
India is currently administering AstraZeneca’s COVID-19 vaccine and a shot developed by Bharat Biotech called Covaxin.
Price Action: JNJ shares are down 1.46% at $160.6, while AZN shares are up 0.67% at $49.83 during market trading hours on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.